Evidence map›Paper›PMID 31897676›Full record

Trial reportAnnals of hematology2020

A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma.

Young-Woong Won, Hyewon Lee, Hyeon-Seok Eom, Jin Seok Kim, Cheolwon Suh, Dok Hyun Yoon, Jung Yong Hong, Hye Jin Kang, Jae Hoon Lee, Won Seog Kim and 10 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Annals of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 14 institutions in 2 countries.

Young-Woong WonDivision of Hematology and Oncology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Seoul, South Korea.
Hyewon LeeHematology-Oncology Clinic, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
Hyeon-Seok EomHematology-Oncology Clinic, Research Institute and Hospital, National Cancer Center, Goyang, South Korea. hseom@ncc.re.kr.ORCID http://orcid.org/0000-0002-0484-2067
Jin Seok KimDepartment of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Cheolwon SuhDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Jung Yong HongDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Hye Jin KangDivision of Hematology and Medical Oncology, Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
Jae Hoon LeeDivision of Hematology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea.
Won Seog KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
Seok Jin KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
Won-Sik LeeDivision of Hematology-Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, South Korea.
Myung Hee ChangDivision of Oncology-Hematology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea.
Young Rok DoDepartment of Hematology-Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea.
Jun Ho YiDivision of Hematology/Oncology, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, South Korea.
Inho KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Jong-Ho WonDivision of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University, Seoul, South Korea.
Kyoungha KimDivision of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University, Seoul, South Korea.
Sung Yong OhDepartment of Internal Medicine, Dong-A University Medical Center, Dong-A University, Busan, South Korea.
Jae-Cheol JoDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
Ulsan College · KRSamsung Medical Center · KRSoonchunhyang University Hospital Seoul · KRYonsei University · KRChung-Ang University Hospital · KRDong-A University · KRGachon University · KRHanyang University Guri Hospital · KRInje University Busan Paik Hospital · KRKeimyung University Dongsan Medical Center · KRKorea Institute of Radiological and Medical Sciences · KRNational Cancer Center · USNational Health Insurance Service Ilsan Hospital · KRSeoul National University Hospital · KR

Funding

Grants of the National Cancer Center NCC 1410210
6 · The paper itself

Abstract

We assessed the efficacy and toxicity of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) combination chemotherapy in patients with refractory or relapsed Hodgkin's lymphoma (HL). This was an open-label, non-randomized, multi-center phase II study. The ESHAOx regimen consisted of intravenous (i.v.) etoposide 40 mg/m

Indexed as

Hodgkin DiseaseAdultAgedAntineoplastic Combined Chemotherapy ProtocolsC-Reactive ProteinCytarabineDisease-Free SurvivalEtoposideFemaleHumansMaleMethylprednisoloneMiddle AgedNeoplasm ProteinsOxaliplatinRecurrenceC-Reactive ProteinCytarabineEtoposideMethylprednisoloneNeoplasm ProteinsOxaliplatinTumor Necrosis Factor-alphaVascular Endothelial Growth Factor AVEGFA protein, humanCytarabineEtoposideHodgkin’s lymphomaMethylprednisoloneOxaliplatin

Identifiers

PMID31897676
OpenAlexW2997754832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.